Menu Back to 09

Track 9: Regulatory

DIA 2017: Driving Insights to Action

This track is composed of 23 sessions addressing global laws, regulations, guidelines, and guidances that govern prescription biopharmaceutical and device product development, approval, and maintenance. Representatives from FDA, EMA, PMDA, MHRA, BfArM, and ICMRA authorities, and other regulatory experts will provide global updates, insights, and discussion on current issues, opportunities, and challenges through interactive forums. Themes include, Global Regulatory Changes and Impact on Global Development Strategies, Global Harmonization/Convergence and Impact on Drug Development, Advances and Innovations to Improve the Practice of Regulatory Affairs, and Regulatory Hot Topics.

Sessions in Regulatory

Sunday, June 23 | Short Courses

View All Short Courses

Included Topic Areas in Regulatory

DIA 2018’s Program and full list of sessions will be available in January. Meanwhile, see what topics and priorities we are designing content for.

  • Implications for global development strategy
  • Expedited registration pathways, novel development strategies and novel approvals
  • Real-world data/real world evidence, biomarkers, clinical outcome assessments, including PROs
  • Common Protocol Template
  • Global harmonization/convergence impact to drug development
  • Expansion of ICH membership as well as other global harmonization activities (e.g., APEC-RHSC, IMDRF)
  • Effect of emerging regulations on global development (e.g., IDMP, import/export, CMC)
  • Effect of emerging regulations on global registration strategies
  • Regulatory considerations for special populations or situations
  • Pediatrics, orphan drugs, ultra-rare diseases, etc.
  • Recent legislation to understand impact on global development plans with regard to differences in EU/US approach
  • Innovation and technologic advancements to improve the practice of regulatory affairs
  • Enhancing regulatory intelligence (AI), improving decision-making in regulatory science
  • Biosimilars
  • Combination Products
  • Complex drug development
  • FDARA/”UFA”
  • Ad/Promo

Who is This Track Designed For?

Professionals involved in: Regulatory affairs and strategy, regulatory operations, regulatory information management, regulatory agencies, government affairs, legal affairs and compliance, policy and intelligence, clinical research and operations, PV, HTA, project management, and service providers developing tools and resources for use by sponsors and CROs.

View Other Tracks


Registration Rates

Back to DIA 2018

Back to DIAglobal.org